NASDAQ:CGEN
Compugen Ltd. Stock News
$2.14
-0.0700 (-3.17%)
At Close: May 16, 2024
We're Not Very Worried About Compugen's (NASDAQ:CGEN) Cash Burn Rate
06:39pm, Friday, 08'th May 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Compugen...
Top Ranked Momentum Stocks to Buy for May 8th
02:52pm, Friday, 08'th May 2020
Top Ranked Momentum Stocks to Buy for May 8th
Compugen Ltd. (CGEN) Q1 2020 Earnings Call Transcript
02:00am, Thursday, 07'th May 2020
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN)Q1 2020 Earnings CallMay 6, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Opera
Compugen Reports First Quarter 2020 Results
11:00am, Wednesday, 06'th May 2020
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2020.
Compugen shares are trading lower after the company reported Q1 earnings results.
12:00am, Wednesday, 06'th May 2020Can This Biotech Shed New Light on Cancer Immunotherapies?
03:57pm, Monday, 04'th May 2020
Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.
What Makes Compugen (CGEN) a New Strong Buy Stock
04:00pm, Thursday, 30'th Apr 2020
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Top Analyst Upgrades and Downgrades: AT&T, Cognex, Disney, J&J, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero and More
01:02pm, Tuesday, 28'th Apr 2020
Tuesday's top analyst upgrades and downgrades included AT&T, Cognex, Johnson & Johnson, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero Energy and Walt Disney.
Compugen sees "encouraging signals" from early-stage cancer trial
10:05am, Monday, 27'th Apr 2020
Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhau
Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
10:00am, Monday, 27'th Apr 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, will present updated results from its ongoing Phase 1 dose escalation study of
